Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax

In this study, we investigated the HDAC inhibitor, panobinostat, in combination with VEN + AZA against AraC-resistant AML cells. Panobinostat treatment downregulated c-Myc and Bcl-xL and upregulated Bim, which enhanced the antileukemic activity of VEN + AZA against AraC-resistant AML cells. In addition, panobinostat alone and in combination with VEN + AZA suppressed oxidative phosphorylation and/or glycolysis in AraC-resistant AML cells. These findings support further development of panobinostat in combination with VEN + AZA for the treatment of AraC-resistant AML.PMID:38373594 | DOI:10.1016/j.bcp.2024.116065

Source: Biochemical Pharmacology - February 19, 2024 Category: Drugs & Pharmacology Authors: Jianlei Zhao Shuangshuang Wu Deying Wang Holly Edwards Jenna Thibodeau Seongho Kim Paul Stemmer Guan Wang Jingji Jin S üreyya Savasan Jeffrey W Taub Yubin Ge Source Type: research